These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 21112854)

  • 41. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Biomarkers in breast cancer.
    Vivanco Md
    Methods Mol Biol; 2010; 593():137-56. PubMed ID: 19957148
    [TBL] [Abstract][Full Text] [Related]  

  • 43. DEAD box 1: a novel and independent prognostic marker for early recurrence in breast cancer.
    Germain DR; Graham K; Glubrecht DD; Hugh JC; Mackey JR; Godbout R
    Breast Cancer Res Treat; 2011 May; 127(1):53-63. PubMed ID: 20499159
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Classification of breast cancer using genetic algorithms and tissue microarrays.
    Dolled-Filhart M; Rydén L; Cregger M; Jirström K; Harigopal M; Camp RL; Rimm DL
    Clin Cancer Res; 2006 Nov; 12(21):6459-68. PubMed ID: 17085660
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up.
    Rydén L; Jirström K; Haglund M; Stål O; Fernö M
    Breast Cancer Res Treat; 2010 Apr; 120(2):491-8. PubMed ID: 20135347
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Translational research and the changing face of breast cancer.
    Dowsett M
    Breast Cancer Res Treat; 2004; 87 Suppl 1():S1-2. PubMed ID: 15597214
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Breast cancer biomarker measurements and standards.
    Cole KD; He HJ; Wang L
    Proteomics Clin Appl; 2013 Jan; 7(1-2):17-29. PubMed ID: 23341234
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Biomarkers in clinical medicine.
    Chen XH; Huang S; Kerr D
    IARC Sci Publ; 2011; (163):303-22. PubMed ID: 22997869
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Breast cancer predictive factor testing: the challenges and importance of standardizing tissue handling.
    Hicks DG; Kushner L; McCarthy K
    J Natl Cancer Inst Monogr; 2011; 2011(42):43-5. PubMed ID: 21672896
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical proteomics and breast cancer: strategies for diagnostic and therapeutic biomarker discovery.
    Bertucci F; Goncalves A
    Future Oncol; 2008 Apr; 4(2):271-87. PubMed ID: 18407739
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Personalized therapy for breast cancer: a dream or a reality?
    Zardavas D; Pugliano L; Piccart M
    Future Oncol; 2013 Aug; 9(8):1105-19. PubMed ID: 23902243
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Research and development for cancer biomarker].
    Nakagawa H
    Nihon Rinsho; 2012 May; 70(5):743-7. PubMed ID: 22619995
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A review on biomarkers for prediction of treatment outcome in gastric cancer.
    Pietrantonio F; De Braud F; Da Prat V; Perrone F; Pierotti MA; Gariboldi M; Fanetti G; Biondani P; Pellegrinelli A; Bossi I; Di Bartolomeo M
    Anticancer Res; 2013 Apr; 33(4):1257-66. PubMed ID: 23564763
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The role of the breast cancer surgeon in personalized cancer care: clinical utility of the 21-gene assay.
    Laronga C; Harness JK; Dixon M; Borgen PI
    Am J Surg; 2012 Jun; 203(6):751-8. PubMed ID: 22516676
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Molecular markers for breast cancer diagnosis, prognosis and targeted therapy.
    Lang JE; Wecsler JS; Press MF; Tripathy D
    J Surg Oncol; 2015 Jan; 111(1):81-90. PubMed ID: 25091830
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Molecular markers for cancer prognosis and treatment: have we struck gold?
    Nowsheen S; Aziz K; Panayiotidis MI; Georgakilas AG
    Cancer Lett; 2012 Dec; 327(1-2):142-52. PubMed ID: 22120674
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and pharmacogenomic biomarkers in breast cancer.
    Paul AK; Schwab RB
    Biomark Med; 2012 Apr; 6(2):211-21. PubMed ID: 22448796
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Biomarkers in heart failure.
    Eleuteri E; Di Stefano A
    Minerva Cardioangiol; 2012 Apr; 60(2):213-26. PubMed ID: 22495170
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Biomarker discovery, development, and implementation in France: a report from the French National Cancer Institute and cooperative groups.
    Andre F; Nowak F; Arnedos M; Lacroix L; Viens P; Calvo F
    Clin Cancer Res; 2012 Mar; 18(6):1555-60. PubMed ID: 22422408
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Individualizing breast cancer treatment-The dawn of personalized medicine.
    Nandy A; Gangopadhyay S; Mukhopadhyay A
    Exp Cell Res; 2014 Jan; 320(1):1-11. PubMed ID: 24051330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.